Shares of Cerulean Pharma Inc. (NASDAQ:DARE) have been assigned a consensus recommendation of “Hold” from the eight ratings firms that are currently covering the company, reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $3.00.

Separately, ValuEngine cut Cerulean Pharma from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st.

Shares of Cerulean Pharma (NASDAQ DARE) opened at 2.80 on Friday. Cerulean Pharma has a one year low of $2.63 and a one year high of $35.80. The stock’s market cap is $8.13 million. The company has a 50-day moving average price of $4.92 and a 200 day moving average price of $7.64.

ILLEGAL ACTIVITY WARNING: “Cerulean Pharma Inc. (DARE) Given Consensus Rating of “Hold” by Analysts” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at

Cerulean Pharma Company Profile

Dare Bioscience, Inc, formerly Cerulean Pharma Inc, is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse.

Analyst Recommendations for Cerulean Pharma (NASDAQ:DARE)

Receive News & Ratings for Cerulean Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerulean Pharma Inc. and related companies with's FREE daily email newsletter.